Evidence map›Paper›PMID 15729383›Full record

ArticleLeukemia2005

Signal transduction and cellular functions of the TEL/ARG oncoprotein.

K Okuda, A Oda, Y Sato, A Nakayama, H Fujita, Y Sonoda, J D Griffin

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

K OkudaDepartment of Health Sciences and Preventive Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan. keiko_o@koto.kpu-m.ac.jp
A Oda
Y Sato
A Nakayama
H Fujita
Y Sonoda
J D Griffin
Hokkaido University · JPKyoto Prefectural University of Medicine · JPHarvard University · USSaitama International Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The TEL/ARG oncogene is formed by t(1;12)(q25;p13) reciprocal translocation and is associated with human leukemia. We have previously demonstrated that the expression of TEL/ARG in Ba/F3 cells results in prolonged viability and hyper-responsiveness to IL-3. To determine the molecular mechanisms, a series of mutants of TEL/ARG were generated, and each cDNA was expressed in Ba/F3 or CHO cells. The PNT domain in TEL and K317 in ARG were essential for both signaling and biological effects. The SH3 domain in ARG was required for hyper-responsiveness to IL-3, but not for prolonged viability. The opposite was true for the SH2 domain in ARG. Mutation of Y314 in TEL, a putative GRB2-binding site, led to reduced viability, and loss of hyper-responsiveness to IL-3. All biological functions were profoundly impaired with deletion of the C-terminus in ARG, despite maintaining high levels of its kinase activity. When expressed in CHO cells, wild-type TEL/ARG induced the formation of fillopodia, in a fashion dependent on the C-terminal portion and intact kinase activity. Thus, these results suggest several critical domains within TEL/ARG necessary for function, and indicate that the signaling pathways necessary for viability, growth factor hyper-responsiveness and cytoskeletal reorganization are likely to be separate.

Indexed as

Actin CytoskeletonAdaptor Proteins, Signal TransducingAnimalsAnti-Bacterial AgentsCell MovementCHO CellsCricetinaeDoxycyclineGene Expression Regulation, LeukemicGRB2 Adaptor ProteinHematopoietic Stem CellsHumansIntegrin beta1Interleukin-3LeukemiaMutagenesisAdaptor Proteins, Signal TransducingAnti-Bacterial AgentsDoxycyclineGRB2 Adaptor ProteinGRB2 protein, humanIntegrin beta1Interleukin-3Oncogene Proteins, FusionProtein-Tyrosine KinasesRecombinant Fusion ProteinsTEL-ARG fusion protein, human

Identifiers

PMID15729383
OpenAlexW2062770251

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.